Cytovale, a San Francisco, CA-based commercial-stage medical diagnostics company, raised $84M in Series C funding.
The round was led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC).
The company intends to use the funds to bring its recently FDA-cleared rapid sepsis diagnosis test – IntelliSep – to more hospital emergency departments (ED) and health systems in the United States.
Led by CEO Ajay Shah, Cytovale provides a rapid laboratory test that offers insights into potential sepsis diagnosis. The test provides a score, which categorizes a patient’s probability of having or developing sepsis within the next three days. Using that score, healthcare providers can quickly determine next steps for treatment with a higher level of confidence, potentially reducing the likelihood of poor outcomes from sepsis, including death.
The company is working with select early access hospitals and health systems to implement the IntelliSep test as part of triage processes for adults presenting to the ED with signs and symptoms of infection.